Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1326
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA ; volume:16 ; number:1 ; day:4 ; month:11 ; year:2021 ; pages:1-4 ; date:12.2021
Molecular neurodegeneration ; 16, Heft 1 (4.11.2021), 1-4, 12.2021
- Urheber
-
Gandy, Sam
Knopman, David S.
Sano, Mary
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13024-021-00490-z
- URN
-
urn:nbn:de:101:1-2022011819231292080520
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gandy, Sam
- Knopman, David S.
- Sano, Mary
- SpringerLink (Online service)
Ähnliche Objekte (12)
FDA efficiency for approval process of COVID-19 therapeutics
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
The case for approval voting
The FDA initiatives for personalized medicine
Talking: Talking Shops
FDA
FDA
FDA
FDA
FDA efficiency for approval process of COVID-19 therapeutics
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
The case for approval voting
The FDA initiatives for personalized medicine
Talking: Talking Shops
FDA
FDA
FDA
FDA
FDA efficiency for approval process of COVID-19 therapeutics
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
The case for approval voting
The FDA initiatives for personalized medicine
Talking: Talking Shops
FDA
FDA
FDA